Literature DB >> 9414659

Increased telomerase activities in human pancreatic duct adenocarcinomas.

M Tsutsumi1, T Tsujiuchi, O Ishikawa, T Majima, M Yoshimoto, Y Sasaki, T Fukuda, H Oohigashi, Y Konishi.   

Abstract

Telomerase is a key enzyme with regard to immortalization of cancer cells and increased activity has been demonstrated in various human malignant neoplasms. Since little is known of its role in pancreatic cancers, we investigated changes in telomerase activity in human pancreatic duct adenocarcinomas and compared the frequency of increased telomerase activity with the presence of K-ras gene mutations. The samples were obtained from 38 pancreatic duct adenocarcinomas and 7 tumor surrounding tissues at surgical resection. Telomerase activity was examined by telomeric repeat amplification protocol assay and terminal restriction fragment (TRF) length was examined by Southern analysis. K-ras mutation was examined by means of polymerase chain reaction-single strand conformation polymorphism analysis. Among 38 pancreatic carcinomas, 32 (84%) exhibited increased telomerase activities with no apparent relation to the histological type of tumor, tumor size, regional lymphnode involvement and distant metastasis or clinical stage. In tissue surrounding the tumor, telomerase activity was not detected. TRF length tended to be reduced in pancreatic carcinomas. Mutations of K-ras gene were found in 24 out of the 38 (63%) cases. Among the 38 cases, 14 showed increased telomerase activity without K-ras mutation and 4 cases showed K-ras mutation without telomerase activity. These results suggest that increased telomerase activity might be a sensitive genetic diagnostic marker and could be a target for future therapy of pancreatic duct carcinomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9414659      PMCID: PMC5921280          DOI: 10.1111/j.1349-7006.1997.tb00317.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  39 in total

1.  K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster.

Authors:  W L Cerny; K A Mangold; D G Scarpelli
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

2.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.

Authors:  M S Redston; C Caldas; A B Seymour; R H Hruban; L da Costa; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

3.  p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters.

Authors:  S Okita; M Tsutsumi; M Onji; Y Konishi
Journal:  Mol Carcinog       Date:  1995-08       Impact factor: 4.784

4.  Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma.

Authors:  M Tada; M Omata; S Kawai; H Saisho; M Ohto; R K Saiki; J J Sninsky
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

5.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

6.  Telomerase activity: a prevalent marker of malignant human prostate tissue.

Authors:  H J Sommerfeld; A K Meeker; M A Piatyszek; G S Bova; J W Shay; D S Coffey
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

7.  Telomere shortening in leukemic cells is related to their genetic alterations but not replicative capability.

Authors:  K Ohyashiki; J H Ohyashiki; T Fujimura; K Kawakubo; T Shimamoto; M Saito; S Nakazawa; K Toyama
Journal:  Cancer Genet Cytogenet       Date:  1994-11

8.  Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions.

Authors:  H Tahara; H Kuniyasu; H Yokozaki; W Yasui; J W Shay; T Ide; E Tahara
Journal:  Clin Cancer Res       Date:  1995-11       Impact factor: 12.531

9.  Comparison of K-ras oncogene activation in pancreatic duct carcinomas and cholangiocarcinomas induced in hamsters by N-nitrosobis(2-hydroxypropyl)amine.

Authors:  M Tsutsumi; Y Murakami; S Kondoh; T Tsujiuchi; K Hohnoki; K Horiguchi; O Noguchi; E Kobayashi; S Okita; T Sekiya
Journal:  Jpn J Cancer Res       Date:  1993-09

10.  Shortened telomere length in hepatocellular carcinomas and corresponding background liver tissues of patients infected with hepatitis virus.

Authors:  K Ohashi; M Tsutsumi; K Kobitsu; T Fukuda; T Tsujiuchi; E Okajima; S Ko; Y Nakajima; H Nakano; Y Konishi
Journal:  Jpn J Cancer Res       Date:  1996-05
View more
  6 in total

Review 1.  Molecular markers of pancreatic cancer: development and clinical relevance.

Authors:  Lucia C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Langenbecks Arch Surg       Date:  2008-02-12       Impact factor: 3.445

2.  Relationship between telomerase activity and its subunit expression and inhibitory effect of antisense hTR on pancreatic carcinoma.

Authors:  Jia-Hua Zhou; Hong-Mei Zhang; Quan Chen; Dong-Dong Han; Fei Pei; Li-Shan Zhang; De-Tong Yang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

3.  Detection of K-ras point mutation and telomerase activity during endoscopic retrograde cholangiopancreatography in diagnosis of pancreatic cancer.

Authors:  Guo-Xiong Zhou; Jie-Fei Huang; Zhao-Shen Li; Guo-Ming Xu; Feng Liu; Hong Zhang
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

Review 4.  Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer.

Authors:  Siuwah Tang; Jillian Bonaroti; Sebnem Unlu; Xiaoyan Liang; Daolin Tang; Herbert J Zeh; Michael T Lotze
Journal:  Pancreas       Date:  2013-07       Impact factor: 3.327

5.  Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells.

Authors:  Katrina M Burchett; Ying Yan; Michel M Ouellette
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

6.  Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells.

Authors:  Katrina M Burchett; Asserewou Etekpo; Surinder K Batra; Ying Yan; Michel M Ouellette
Journal:  Oncotarget       Date:  2017-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.